The ALBIOS trial showed that in patients with severe sepsis the use of 20% albumin to maintain serum albumin above 3 g/dl was associated with higher mean arterial pressure and less FO; moreover, the septic shock subgroup showed a survival benefit.40 The gene discussed is ALB; the disease is Sepsis.